GIOTRIF ® data published in The Lancet Oncology
GIOTRIF ® data published in The Lancet Oncology (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Benefits of Pradaxa ® maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure
Benefits of Pradaxa ® maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Type 2 Diabetes: European Commission approves Jardiance ® (empagliflozin)
Type 2 Diabetes: European Commission approves Jardiance ® (empagliflozin) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New data on safety and efficacy of Pradaxa ® in treatment of acute deep vein thrombosis and pulmonary embolism
New data on safety and efficacy of Pradaxa ® in treatment of acute deep vein thrombosis and pulmonary embolism (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

U.S. FDA grants Breakthrough Therapy Designation to Pradaxa ® (dabigatran etexilate) specific investigational antidote
U.S. FDA grants Breakthrough Therapy Designation to Pradaxa ® (dabigatran etexilate) specific investigational antidote (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New Pradaxa ® clinical study to explore practical management of patients with atrial fibrillation undergoing ablation
New Pradaxa ® clinical study to explore practical management of patients with atrial fibrillation undergoing ablation (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Pradaxa ® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism
Pradaxa ® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Type 2 Diabetes: Jardiance ® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials
Type 2 Diabetes: Jardiance ® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New GIOTRIF ® data shows over 1 year survival
New GIOTRIF ® data shows over 1 year survival (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Extensive experience in clinical practice and expanding research programme support use of Pradaxa ® for clot prevention
Extensive experience in clinical practice and expanding research programme support use of Pradaxa ® for clot prevention (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New Pradaxa ® data to be presented at the ESC Congress 2014
New Pradaxa ® data to be presented at the ESC Congress 2014 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Innovative protection against Bovine Viral Diarrhea: Boehringer Ingelheim launches Bovela ® in Europe
Innovative protection against Bovine Viral Diarrhea: Boehringer Ingelheim launches Bovela ® in Europe (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New large-scale study to investigate effect of tiotropium + olodaterol Respimat ® on exacerbations in COPD
New large-scale study to investigate effect of tiotropium + olodaterol Respimat ® on exacerbations in COPD (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

OFEV ® (nintedanib*) approved in the EU for the treatment of IPF
OFEV ® (nintedanib*) approved in the EU for the treatment of IPF (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Efficacy and Safety Profile of Pradaxa ® (dabigatran etexilate) Repeatedly Confirmed
Efficacy and Safety Profile of Pradaxa ® (dabigatran etexilate) Repeatedly Confirmed (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Boehringer Ingelheim invests €100 million: Expanded Respimat® production in Dortmund
Boehringer Ingelheim invests €100 million: Expanded Respimat® production in Dortmund (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Asthma: new indication for Spiriva ® (tiotropium) Respimat®* in the EU may offer millions of adults a significant advance in asthma care
Asthma: new indication for Spiriva ® (tiotropium) Respimat®* in the EU may offer millions of adults a significant advance in asthma care (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

" European Respiratory Society International Congress 2014 TONADO ™ - further lung function and quality of life benefits with tiotropium + olodaterol Respimat® FDC* in COPD "
" European Respiratory Society International Congress 2014 TONADO ™ - further lung function and quality of life benefits with tiotropium + olodaterol Respimat® FDC* in COPD " (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

ESC Congress 2014 Hot Line Session: Favourable effect of Pradaxa ® on kidney function over time compared to warfarin
ESC Congress 2014 Hot Line Session: Favourable effect of Pradaxa ® on kidney function over time compared to warfarin (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Boehringer Ingelheim ’s OFEV™ (nintedanib*) approved by the FDA for the treatment of idiopathic pulmonary fibrosis
Boehringer Ingelheim ’s OFEV™ (nintedanib*) approved by the FDA for the treatment of idiopathic pulmonary fibrosis (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Asthma: U.S. FDA approves new indication for SPIRIVA ® Respimat®
Asthma: U.S. FDA approves new indication for SPIRIVA ® Respimat® (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

FDA approves Boehringer Ingelheim ’s Stiolto™* Respimat® as once-daily maintenance treatment for COPD
FDA approves Boehringer Ingelheim ’s Stiolto™* Respimat® as once-daily maintenance treatment for COPD (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New data show benefit of tiotropium/olodaterol Respimat ® from the start of COPD maintenance therapy
New data show benefit of tiotropium/olodaterol Respimat ® from the start of COPD maintenance therapy (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Type 2 diabetes: Synjardy ® (empagliflozin/metformin hydrochloride) approved in the European Union
Type 2 diabetes: Synjardy ® (empagliflozin/metformin hydrochloride) approved in the European Union (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New GIOTRIF ® data published in The Lancet Oncology
New GIOTRIF ® data published in The Lancet Oncology (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

GIOTRIF ® Asian EGFR M+ NSCLC subgroup analysis
GIOTRIF ® Asian EGFR M+ NSCLC subgroup analysis (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New advance in COPD maintenance treatment, Spiolto ® Respimat®, approved in first European countries
New advance in COPD maintenance treatment, Spiolto ® Respimat®, approved in first European countries (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Respimat ® success story: Boehringer Ingelheim invests EUR 72 million in production capacity in Ingelheim
Respimat ® success story: Boehringer Ingelheim invests EUR 72 million in production capacity in Ingelheim (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Vargatef ® (nintedanib) approved in the EU for NSCLC
Vargatef ® (nintedanib) approved in the EU for NSCLC (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Boehringer Ingelheim Welcomes the Inclusion of OFEV ® (nintedanib*) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim Welcomes the Inclusion of OFEV ® (nintedanib*) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Asthma: Boehringer Ingelheim announces U.S. FDA filing acceptance of NDA for Spiriva ® Respimat® in asthma
Asthma: Boehringer Ingelheim announces U.S. FDA filing acceptance of NDA for Spiriva ® Respimat® in asthma (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Safety and efficacy of Pradaxa ® (dabigatran etexilate) reconfirmed in clinical setting for VTE prevention after total knee or hip replacement
Safety and efficacy of Pradaxa ® (dabigatran etexilate) reconfirmed in clinical setting for VTE prevention after total knee or hip replacement (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

European Medicines Agency (EMA) approves the use of Ingelvac CircoFLEX ® during pregnancy and lactation in sows
European Medicines Agency (EMA) approves the use of Ingelvac CircoFLEX ® during pregnancy and lactation in sows (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

CHEST: New Sub-Analyses Show Improvement in COPD Patient Outcomes with Spiolto ® Respimat®
CHEST: New Sub-Analyses Show Improvement in COPD Patient Outcomes with Spiolto ® Respimat® (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

FDA Approves Praxbind ® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate)
FDA Approves Praxbind ® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New data demonstrate sustained long-term efficacy of OFEV ®* on slowing disease progression and safety in patients with IPF
New data demonstrate sustained long-term efficacy of OFEV ®* on slowing disease progression and safety in patients with IPF (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Jardiance ® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial
Jardiance ® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa ® than with warfarin
Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa ® than with warfarin (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New tumour models could lead to more effective treatments
The incidence of cancer in Europe is increasing but many potential new drug treatments are found to be ineffective when tested on patients. An EU and industry-funded project has investigated new models of tumours to help researchers discover more effective treatments and boost survival rates. (Source: EUROPA - Research Information Centre)
Source: EUROPA - Research Information Centre - November 27, 2017 Category: Research Source Type: news

Is there a link between poultry and infertility? We deserve to know | Letters
I have been told that no research is being done in Britain to establish whether there is a causal factor between eating chicken and declining male sperm counts, writesBaroness Jean CorstonLetters and articles on the apparent decline in male fertility, and its probable causes, have been in our newspapers for years, with the cause variously ascribed to diet, exerciseor the environment. Nearly 20 years ago, as a member of the House of Commons select committee on agriculture, we held an inquiry into the poultry industry. Some of us were appalled by the industrialisation of poultry production, with birds crowded together and gi...
Source: Guardian Unlimited Science - November 24, 2017 Category: Science Authors: Letters Tags: Food science & drink industry Animal welfare Farming Farm animals Environment Biology Human biology Business UK news Politics World news Medical research Source Type: news

High-throughput 3D printers for complex ceramic parts
Additive manufacturing is re-defining what can or cannot be accomplished in the production of parts, and research continues to redefine what can and cannot be accomplished with additive manufacturing. An EU-funded project has set out to break new ground for the 3D printing of complex ceramic components. (Source: EUROPA - Research Information Centre)
Source: EUROPA - Research Information Centre - November 24, 2017 Category: Research Source Type: news

Together for sustainable cities: an international research alliance
The world's cities account for less than 3% of its land surface, but they are already home to much of its population. By 2050, two-thirds of us are projected to live in urban areas, where joined-up management of food, water and energy will be increasingly important. A wave of partly EU-funded projects is about to explore this sustainability issue. (Source: EUROPA - Research Information Centre)
Source: EUROPA - Research Information Centre - November 23, 2017 Category: Research Source Type: news

An elegant solution to a quantum problem
The theory of electromagnetic polarisation has been under development for more than 150 years since British scientist Michael Faraday provided the first experimental evidence of the interaction between electricity, magnetism and light. An EU-funded project is now helping to fit together the missing pieces of the puzzle. (Source: EUROPA - Research Information Centre)
Source: EUROPA - Research Information Centre - November 22, 2017 Category: Research Source Type: news

Fighting hunger by cutting food waste
Worldwide, we waste around 1.3 billion tonnes of food a year, while nearly a billion people go hungry. An EU-funded project has created an online community to tackle the problem by sharing knowledge and redistributing food. (Source: EUROPA - Research Information Centre)
Source: EUROPA - Research Information Centre - November 22, 2017 Category: Research Source Type: news

Breathe easier - smart sensors for healthier indoor air
Stuffy office environments and poor air quality in schools, hospitals and factories could soon be a distant memory thanks to low-cost smart sensor and ventilation-control technology capable of intelligently detecting and removing hazardous airborne substances. The technology was developed through EU-funded research. (Source: EUROPA - Research Information Centre)
Source: EUROPA - Research Information Centre - November 22, 2017 Category: Research Source Type: news

Better drug design: bioengineering and chemical synthesis duo
The EU-funded SWEETOOLS project aims to improve our understanding of the role of sugars in human biology. Exploring optimised versions of biosynthesised proteins combined with chemically synthesised drugs could help the development of novel biomedicines and vaccines targeting, for example, influenza. (Source: EUROPA - Research Information Centre)
Source: EUROPA - Research Information Centre - November 22, 2017 Category: Research Source Type: news

Perseverance pays off for twin-ship lift, load and lever system
An EU-funded solution for an innovative twin-ship lift, load and lever system has sparked considerable interest from oil platform operators and the oil and gas industry in general. With the design now fully validated, and with international backers on board, construction of the system begins in earnest. (Source: EUROPA - Research Information Centre)
Source: EUROPA - Research Information Centre - November 22, 2017 Category: Research Source Type: news

Creating a shared traffic safety culture
To stay safe on the roads, we need good infrastructure, alert road-users and effective technology. But what about a general safety culture? A team of researchers from countries with very different approaches to road-use is developing a cultural approach to road safety with the ultimate objective of cutting traffic accident numbers. (Source: EUROPA - Research Information Centre)
Source: EUROPA - Research Information Centre - November 22, 2017 Category: Research Source Type: news

Ocean-monitoring sensor system makes waves
An EU-funded project has developed and deployed cost-effective marine sensors to monitor and provide a more complete picture of the health of our planet's oceans. Some of the sensors are already on the market and patents are pending. (Source: EUROPA - Research Information Centre)
Source: EUROPA - Research Information Centre - November 22, 2017 Category: Research Source Type: news

Networking for EU wine production
The popping of corks and glugging of a good wine may not be at threat just yet, but if the diseases threatening Europe's vineyards have their way, they could be. EU-funded researchers therefore have very good reason to network around wine - they are building a knowledge bank to help vineyard owners protect their crops and keep the wine flowing. (Source: EUROPA - Research Information Centre)
Source: EUROPA - Research Information Centre - November 22, 2017 Category: Research Source Type: news